Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sunscreen study shows promise for oily, aging skin

NCT ID NCT07310706

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a facial sunscreen in 73 adults aged 30 to 55 with oily skin and visible aging. Over eight weeks, researchers measured changes in wrinkles, fine lines, oiliness, and pore appearance using skin exams and special equipment. The goal was to see if the sunscreen could improve both oil control and aging signs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

73 people

The number who actually took part.

Started

Aug 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. For group I: 30 to 44 years of age; For group II: 45 to 55 years of age; 2. Skin Type I to VI according to Fitzpatrick's classification. For each group: I. Fitzpatrick I and II: at least 8 participants II. Fitzpatrick III and IV: at least 8 participants III. Fitzpatrick V and VI: at least 8 participants 3. Participants of any ethnicity according to IBGE criteria; 4. Participants with oily or combination skin and oily shine on the face, both self-declared (through applied questionnaire) and confirmed by the dermatologist (from 2 points for oil shine by the modified Griffith scale from 0 to 9) at inclusion. For group I: oiliness will also be confirmed by Sebumeter (value above 100 AU for inclusion); 5. Participants self-declared to have enlarged pores, confirmed by dermatologist; 6. Participants who show signs of mild to moderate aging (2 to 6 points for the parameters of wrinkles, fine lines, and skin roughness based on the modified Griffith scale of 0-9 points), confirmed by dermatologist at inclusion; 7. Participant reports, at the time of inclusion, that he/she is concerned with at least one of the following parameters related to the appearance of facial skin: I. Fine lines II. Wrinkles III. Roughness/uneven texture 8. Good general health, based on participant-reported medical history; 9. Able to read, write, speak and understand Portuguese; 10. For male participants: agree to shave 48 hours before study visits; 11. Person who signed the ICF and ICIU; 12. Intend to complete the study and are willing and able to follow all the instructions of the study. Exclusion Criteria: 1. Have known allergies or adverse reactions to common topical skin care products, including facial sunscreen; 2. Have a skin condition that may influence the outcome of the study (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer); 3. Present primary/secondary lesions (e.g., scars, ulcers, vesicles, irritation resulting from the removal of facial hair) in the test areas; 4. Report having Type 1 or Type 2 diabetes or taking insulin or other antidiabetic medication; 5. Using medications that could mask an adverse event (AE) or influence the results of the study, including: * Immunosuppressive or steroidal medications within 2 months prior to the first visit * Non-steroidal anti-inflammatory drugs within 5 days prior to the first visit * Antihistamines within 2 weeks prior to the first visit * Antibiotics (oral or topical), hormonal therapy (except hormonal contraception methods), insulin, inhaled steroids (except prescribed for temporary allergy relief) within 1 month prior to the first visit. 6. Participants who have undergone invasive aesthetic or dermatological treatments in the test area (face) within 2 months prior to the first visit; 7. Menopausal or postmenopausal women (except for perimenopausal women who are eligible for the study); 8. Presence of excess hair in the evaluation area (face) that may interfere with instrumental evaluations. In the case of men, they will be instructed to shave 48 hours before visits; 9. Use of any products that may interfere with study assessments, at the discretion of the dermatologist; 10. Participants who have undergone chemical and/or physical peeling, laser, or similar aesthetic treatments within 6 months prior to the study; 11. Participants who reported being pregnant, planning to become pregnant, or breastfeeding during the study; 12. Have a history of or currently have a health condition/situation that could put the subject at significant risk, confound the results of the study, or significantly interfere with their participation in the study; 13. Be simultaneously participating in another clinical study; 14. Be an employee/contractor or close relative of the PI, Study Site or Sponsor; 15. Participants who practice activities (leisure or work) with intense sun exposure; 16. Smoking participants (Note: participants living with smokers may be eligible, provided that, at the discretion of the investigator, the participant's exposure to cigarettes does not interfere with or confound the results of the study. The participant's coexistence with a smoker must be reported as informative data).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Oily skin aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CIDP do Brasil Pesquisas Clínicas LTDA

    Rio de Janeiro, 20231-048, Brazil